Table 1 Clinical responses and patient-reported outcomes (PROs) at the baseline period and after week 12 of erenumab treatment
From: MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention
Variable | Baseline | Week 12 | Difference |
|---|---|---|---|
MMDs | 17.1Â days | 11.0Â days | -6.5Â days |
MHDs | 23.5Â days | 14.9Â days | -8.6Â days |
HIT-6 score | 68.8 points | 57.2 points | -11.6 points |
MIDAS score | 101.9 points | 66.9 points | -35 points |
MOH | 70% | 43.4% | -26.6% |